Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial

Yongjun Wang,1,2 Claiborne Johnston,3 Philip M Bath,4 Xia Meng,1,2 Jing Jing,1,2 Xuewei Xie,1,2 Anxin Wang,1,2 Yuesong Pan,1,2 Anding Xu,5 Qiang Dong,3 Yilong Wang,1,2 Xingquan Zhao,1,2 Zixiao Li,1,2 Hao Li,1,2 For the CHANCE-2 Investigators

INTRODUCTION AND RATIONALE

In patients with acute non-disabling cerebrovascular events, including those with acute minor stroke or transient ischaemic attack (TIA), the subsequent recurrent stroke and cardiovascular events are more than 6% in the first year.1 2 As shown in Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial and the Platelet-Oriented Inhibition in New TIA and Minor Ischaemic Stroke (POINT) trial, a lower risk of stroke recurrence was observed with a combination of clopidogrel and aspirin (clopidogrel–aspirin) than with aspirin alone.3 4 However, the choice of an optimal dual antiplatelet therapy regimen for patients with strokes requires a tailored approach based on the characteristics of the patient. The genetic substudy of the CHANCE trial showed that clopidogrel plus aspirin reduced the risk of stroke recurrence in non-carriers of the cytochrome P450 2C19 (CYP2C19) loss-of-function (LOF) alleles compared with aspirin alone but not in carriers.5 More recently, the substudy of POINT failed to reproduce the above findings as seen in the CHANCE trial, possibly from a limited statistical power.6

In addition, a meta-analysis of 15 studies that included 4762 patients with stroke or TIA found that carriers of CYP2C19 LOF alleles were at higher risk of vascular events than non-carriers when taking clopidogrel.7

Ticagrelor is a reversible oral antagonist directly blocking the P2Y12-adenosine diphosphate receptor that needs no catalolite activation, which in turn yields greater mean levels of platelet inhibition than clopidogrel.8 9 From the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes trial involving participants with acute ischaemic stroke or TIA, ticagrelor was not found to be more effective than aspirin in reducing
the risk of 90-day vascular events. However, among the Asian patients, a tendency towards better efficacy was seen in a subgroup analysis. The Platelet Reactivity in Acute Stroke or Transient Ischaemic Attack trial showed that participants with ischaemic stroke or TIA who were treated with ticagrelor plus aspirin (ticagrelor–aspirin) had a lower proportion of high platelet reactivity than those who were treated with clopidogrel–aspirin, particularly in those who were CYP2C19 LOF allele carriers. The Acute Stroke or Transient Ischaemic Attack TIA who were treated with ticagrelor plus aspirin (ticagrelor–aspirin) had a lower proportion of high platelet reactivity in Acute Stroke or Transient Ischaemic Attack was seen in a subgroup analysis.

The Platelet Reactivity in Acute Stroke or Transient Ischaemic Attack Trial designed to test such hypothesis. The intention of this trial is to evaluate the safety and efficacy of ticagrelor–aspirin versus clopidogrel–aspirin for minor stroke or high-risk TIA patients who were CYP2C19 LOF allele carriers. This article describes the design of the CHANCE-2 trial and is a summary of protocol.

METHODS

**Design and patients population**

CHANCE-2 is a randomised, double-blind, placebo-controlled multicentre trial. Patients with CYP2C19 LOF alleles are randomised with 1:1 to one of the two strategies (ticagrelor–aspirin or clopidogrel–aspirin) within 24 hours of the onset of cerebrovascular events. All participants will be followed for 3 months on study intervention, with another 9 months of follow-up on standard of care. The study design of the CHANCE-2 is shown in figure 1. The trial will enrol subjects age ≥40 years with acute non-disabling ischaemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score ≤3 or high-risk TIs (ABCDE score ≥24). Once randomised, they will be treated with study drug within 24 hours of symptoms onset. Figure 2 lists the summary of inclusion and exclusion criteria. Prior to initiating the study, each clinical site obtains institutional review board (IRB) approval for the protocol, informed consent, and materials used to recruit subjects. Participants from 240 hospitals in China will be enrolled in CHANCE-2.

**Genotyping**

In this study, a novel point-of-care genetic test platform will be used to identify carriers of CYP2C19 LOF alleles including poor metabolisers with at least two *2 or *3 alleles (*2/*2, *2/*3, or *3/*3) or intermediate metabolisers with one *2 or *3 allele (*1/*2 or *1/*3). The CYP2C19 genotyping will be implemented by the GMEX Point-of-Care Genotyping system, including a portable DNA analyser, genotyping reagents, and a buccal sample collection kit. The system uses non-invasive sampling by buccal swab and integrates automated steps of DNA extraction, PCR-based amplification, fluorescent signal detection and genotype determination. The system integrates controls to monitor the performance of a run and ensure ongoing quality from the GMEX system. The analysis includes the single nucleotide polymorphisms CYP2C19*2 (681G>A, rs4244285), CYP2C19*3 (656G>A, rs4986893), and CYP2C19*17 (~806C>T, rs12248560), which will be genotyped on screening. The average result turn-around-time for the method of GMEX is 85 min.

**Randomisation**

Participants will be randomised (1:1) to receive either ticagrelor–aspirin or clopidogrel–aspirin. A randomisation sequence will be generated centrally using random-permuted fixed-size blocks methods from the Statistics and Data Centre at the China National Clinical Research Centre for Neurological Diseases. The randomisation computer program makes the treatment assignment based on the current status of treatment group distribution within each clinical centre as well as overall balance of treatment assignment. Following randomised allocation, the study intervention will be administered to the patient as early as possible.

**Intervention**

Eligible participants are randomly assigned to one of two arms:

**Ticagrelor–aspirin group**

A 180 mg loading dose of Ticagrelor on day 1, followed by 90 mg two times per day on days 2–90 plus a 75–300 mg loading dose of aspirin, followed by 75 mg daily for 21 days;

**Clopidogrel–aspirin group**

A 300 mg loading dose of clopidogrel on day 1, followed by 75 two times per day on days 2–90 plus a 75–300 mg loading dose of aspirin followed by 75 mg daily for 21 days.

Patient will take the first dose of the study drug on the first visit. Then, for the next 12 weeks, the study drug should be taken twice daily, 12 hours apart. Once the study period is over at the end of 12th week, the treating physician will decide what antiplatelet drug to be continued. All participants will be followed for 1 year.
Inclusion and exclusion criteria

1. ≥ 40 years;
2. Acute cerebral ischemic event due to:
   - Acute non-disabling ischemic stroke (NIHSS ≤ 3 at the time of randomization) or,
   - TIA with moderate-to-high risk of stroke recurrence (ABCD² score ≥ 4 at the time of randomization);
3. Can be treated with study drug within 24 hours of symptoms onset*;
4. CYP2C19 loss-of-function allele carriers;
5. Informed consent signed.

Exclusion criteria

1. Malformation, tumor, abscess or other major non-ischemic brain disease (e.g., multiple sclerosis) on baseline head CT or MRI.
2. Isolated or pure sensory symptoms (e.g., numbness), isolated visual changes, or isolated dizziness/vertigo without evidence of acute infarction on baseline head CT or MRI.
3. Iatrogenic causes (angioplasty or surgery) of minor stroke or TIA.
4. Preceding moderate or severe dependency (modified Rankin scale [mRS] score 3-5).
5. Contraindication to ticagrelor, clopidogrel or ASA.
   - Known allergy
   - Severe hepatic or renal insufficiency (severe hepatic insufficiency defined as ALT 2 times greater than ULN or AST 2 times greater than ULN; severe renal insufficiency defined as SCr 1.5 times greater than ULN)
   - Severe heart failure (NY Heart Association class III and IV)
   - History of hemostatic disorder or systemic bleeding
   - History of thrombocytopenia or neutropenia
   - History of drug-induced hematologic or hepatic abnormalities
   - Low white blood cell (<2 x 10⁹/l) or platelet count (<100 x 10⁹/l)
6. Hematocrit (HCT) < 30%.
7. Clear indication for antiocoagulation (presumed cardiac source of embolus, e.g., atrial fibrillation, prosthetic cardiac valves known or suspected endocarditis).
8. History of intracranial hemorrhage or amyloid angiopathy.
9. History of aneurysm (intracranial aneurysm and peripheral aneurysm).
10. History of asthma or COPD (chronic obstructive pulmonary disease).
11. High-risk for bradycardia (first-degree or second-degree AV block caused by sinus node disease, and brady-arrhythmic syncpe without pacemaker).
13. Anticipated requirement for long-term (> 7 days) non-steroidal anti-inflammatory drugs (NSAIDs).
14. Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months.
15. Scheduled for surgery or interventional treatment requiring study drug cessation.
16. Severe non-cardiovascular comorbidity with life expectancy < 3 months.
17. Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders.
18. Dual antiplatelet treatment in 72 hours before randomization.
19. Current treatment (last dose given within 10 days before randomization) with heparin therapy or oral anti coagulation.
20. Intravenous thrombolytic therapy (such as intravenous rtPA) or mechanical thrombectomy within 24 hours prior to randomization.
21. Gastrointestinal bleed within 3 months or major surgery within 30 days.
22. Diagnosis or suspicious diagnosis of acute coronary syndrome.
23. Participation in another clinical study with an experimental product during the last 30 days.
24. Currently receiving an experimental drug or device.
25. Pregnant, currently trying to become pregnant, or of child-bearing potential and not using birth control.

*Symptom onset is defined by the “last see normal” principle.

Figure 1  CHANCE-2 study design. CHANCE-2, Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischaemic attack ; ASA , aspirin; ULN, upper limit of normal; ALT, alanine aminotransferase; AST, aspartate transaminase; AV, atrioventricular.
Primary outcomes
The primary efficacy outcome is any stroke (ischaemic or haemorrhagic) within 3 months. Definitions of stroke are provided in online supplemental table 1.

Secondary outcomes
Secondary outcomes include the following events: (1) Any new stroke events within 30 days and 1 year; (2) New clinical vascular events including stroke, TIA, myocardial infarction and vascular deaths within 3 months and 1 year; (3) New ischaemic stroke within 3 months and 1 year; (4) Disabling stroke (Modified Rankin Scale score, mRS >1) at 3 months and 1 year; (5) Incidence and severity of recurrent stroke and TIA during follow-up to 3 months and 1 year. Severity is measured using a six-level ordered categorical scale that incorporates the mRS: fatal stroke/severe non-fatal stroke (mRS 4 or 5)/moderate stroke (mRS 2 or 3)/mild stroke (mRS 0 or 1)/TIA/no stroke-TIA; (6) Neurological impairment at 3 months (NIHSS increased ≥4 from baseline); (7) Quality of Life (EuroQol-5dimension) scale. The influence on treatment effect of age, gender, body mass index, index event type (TIA vs minor stroke), time from index event to randomisation, aetiology subtype, diabetes mellitus, hypertension, type of LOF allele, previous ischaemic stroke or TIA, prior antiplatelet therapy, prior statin therapy, prior smoking status and symptomatic intracranial and extracranial artery stenosis will be evaluated in subgroup analyses.

Safety outcomes
The primary safety outcome is severe or moderate bleeding event within 3 months. The bleeding event is defined by the criteria from the Global Utilisation of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial.14 Severe haemorrhage is defined as fatal or intracranial haemorrhage or other haemorrhage causing haemodynamic compromise that requires blood or fluid replacement, inotropic support or surgical intervention. Moderate haemorrhage is defined as bleeding that required transfusion of blood but does not lead to haemodynamic compromise requiring intervention. Other secondary safety outcomes include the following events within a 3-month and 1-year time frame: (1) Incidence of severe bleedings or moderate bleedings (GUSTO definition) at 1 year; (2) Bleeding events; (3) Mortality; (4) Adverse events (AEs)/serious adverse events (SAEs) reported by the investigators.

Data safety and monitoring board
To ensure ethically conduct of the trial and patient safety, the data safety and monitoring board (DSMB) will meet per protocol and monitor the progress of the trial. Members of DSMB do not participate in the trial and their responsibilities are defined by the trial Executive Committee prior to the beginning of the trial. DSMB will provide their recommendations in written statement to the Chairs of trial Steering Committee after each meeting.

Sample size
The sample size calculation is based on the rate of the primary outcome (3-month risk of stroke) and estimated effect size. We used the following assumptions: (1) Significance level of 0.048 for a two-sided test; (2) Statistical power of 90%; (3) 3-month rate of stroke event is 9.4% in control group based on the data from the CHANCE trial; (4) Proportional risk reduction of 25% (Rate ratio=0.75); (5) of 5% over 3 months. We estimated that 6396 eligible patients (3198 for each treatment group) are required. As 58.8% of patients are CYP2C19 LOF allele carriers,5 we need to screen about 10 878 patients in total.

Interim analysis
The interim analysis will focus on patient recruitment, baseline comparability of treatment arms, sample sizes with regard to event rates, loss to follow-up, adverse effects data and effect of treatment on the primary endpoints. We plan one interim analysis when 60% of total patients have undergone randomisation and completed the follow-up. The sample size is inflated to account for one interim analysis of the primary efficacy outcome with the use of an O’Brien-Fleming spending function, and a p<0.008 is considered to be statistically significant during the interim analysis. In the final analysis, a p<0.048 is considered to be statistically significant in the current study. Trial investigators will be blinded to the interim outcome results.

Statistical analyses
An intention-to-treat analysis will be used for all participants randomised to an intervention group. Participants will be censored at their last follow-up assessment when experiencing a clinical event, at the end of study, or at the time of withdrawal from the study. Statistically, the cumulative risk of any ischaemic or haemorrhagic event will be reported as a Kaplan-Meier estimates during the 90-day follow-up. Cox proportional hazards methods will be used for HR calculation at 95% CIs. The treatment effect will be assessed by the log-rank test. This approach is to maximise the time-dependent information in the trial while still acknowledge the ease of interpretation of
risks. Accounting for a single interim analysis, a p value of 0.048 will be considered to indicate statistical significance for the primary outcome. Detailed analysis plans will be given in the statistical analysis plan before the database is locked and the blind is broken.

### Study organisation

The Trial Steering Committee provides oversight and strategic input and will meet twice yearly. The Trial Management Committee runs the trial on a day-to-day basis and is based at the CHANCE-2 Trial Coordinating Centre of the China National Clinical Research Centre for Neurological Diseases. Outcomes, SAEs, and brain imaging are adjudicated by trained assessors masked to treatment assignment.

### DISCUSSION

CHANCE-2 will address a major issue in secondary prevention in those TIA or minor stroke patients who are CYP2C19 LoF allele carriers. Furthermore, the safety and efficacy of ticagrelor–aspirin or clopidogrel–aspirin will be assessed.

Two recent RCTs revealed that the short term clopidogrel–aspirin therapy is beneficial after acute minor stroke or TIA. However, several studies have showed the higher risk of poor clinical outcomes in CYP2C19 LOF allele carriers who receiving clopidogrel. A genetic substudy of the Secondary Prevention of Small Subcortical Strokes trial reported that patients with one CYP2C19 LoF allele carriers had higher odds of stroke recurrence compared with non-carriers. A preplanned substudy of the CHANCE trial found that CYP2C19 LoF carriers had 1.5 times the risk of recurrent stroke as non-carriers at 90 days. To date, there is no evidence from randomised trials for a direct comparison of treatment effect between ticagrelor and clopidogrel with aspirin added on for secondary stroke prevention. Clopidogrel–aspirin is still the approved option for secondary stroke prevention in patients with acute non-disabling cerebrovascular events.

### SUMMARY AND CONCLUSIONS

The CHANCE-2 trial will produce reliable data on whether ticagrelor–aspirin is superior to the recommendations from current guidelines, clopidogrel–aspirin, for the prevention of recurrent stroke in patients who already have experienced an acute minor stroke or high-risk TIA and are carriers of CYP2C19 LoF alleles.
trial (acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes). *Stroke* 2017;48:167–73.


